http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101262479-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-101 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0092 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-183 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2010-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101262479-B1 |
| titleOfInvention | Core / shell nanocomposite with excellent biocompatibility, preparation method thereof, MRI contrast agent, NCT reagent for cancer treatment |
| abstract | BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a core / shell nanocomposite having excellent biocompatibility and a method for manufacturing the same. Specifically, a core composed of gadolinium oxide (Gd 2 O 3 ) nanoparticles and a silica shell surrounding a core outer surface (SiO 2 shell) And a core / shell nanocomposite having a PMPC (Poly (2-methacryloyloxyethyl Phosphorylcholine)) coating layer formed on the surface of the silica shell, the nanocomposite of the present invention is non-toxic, and has excellent biocompatibility and long-term blood circulation. It is suitable for use as MRI contrast agent because of its excellent dispersion stability and excellent contrast effect. It is also suitable for use in neutron capture therapy (NCT) reagents for the treatment of cancer through neutron capture therapy (NCT). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018164502-A1 |
| priorityDate | 2010-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.